Insulet (PODD) to Release Earnings on Thursday

Insulet (NASDAQ:PODD - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Insulet to post earnings of $0.93 per share and revenue of $612.31 million for the quarter. Insulet has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The company's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter last year, the company posted $0.73 EPS. On average, analysts expect Insulet to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Insulet Price Performance

Shares of NASDAQ PODD traded down $3.49 during trading hours on Friday, reaching $284.91. 567,392 shares of the stock traded hands, compared to its average volume of 489,973. The company has a market capitalization of $20.05 billion, a P/E ratio of 51.24, a price-to-earnings-growth ratio of 2.57 and a beta of 1.35. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21. Insulet has a 52-week low of $173.00 and a 52-week high of $329.33. The company's 50-day simple moving average is $302.39 and its two-hundred day simple moving average is $282.37.

Insider Activity

In related news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president directly owned 23,180 shares in the company, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.39% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Insulet stock. NewEdge Advisors LLC boosted its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 44.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 207 shares of the medical instruments supplier's stock after purchasing an additional 64 shares during the quarter. NewEdge Advisors LLC's holdings in Insulet were worth $54,000 as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PODD. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Wall Street Zen downgraded Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Wells Fargo & Company set a $322.00 target price on Insulet in a report on Monday, April 28th. Finally, Oppenheimer boosted their target price on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average price target of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.